ClearPoint Neuro feliciteert partner AviadoBio met de behandeling van de eerste patiënt in klinisch onderzoek ASPIRE-FTD, waarin AVB-101 wordt geëvalueerd voor frontotemporale dementie met GRN-mutaties
April 17, 2024 15:21 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californië, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (het “bedrijf”), een internationaal bedrijf dat zich toelegt op hulpmiddelen, cel- en...
ClearPoint Neuro felicita a su socio AviadoBio por el primer paciente tratado en su ensayo clínico ASPIRE-FTD que evalúa AVB-101 en personas con demencia frontotemporal con mutaciones en el gen GRN
April 17, 2024 15:21 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, California, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (la «empresa»), una compañía global de dispositivos, células y terapia génica que ofrece navegación...
ClearPoint Neuro si congratula con il proprio partner AviadoBio per il primo paziente trattato nello studio clinico ASPIRE-FTD, che valuta la terapia genica sperimentale AVB-101 per la demenza frontotemporale con mutazioni GRN
April 17, 2024 15:21 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, California, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (la “Società”), un’azienda globale di dispositivi, cellule e terapie geniche che offre una...
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
April 17, 2024 15:21 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalifornien, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (das „Unternehmen“), ein globales Unternehmen für Geräte, Zellen und Gentherapie, das präzise...
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN
April 17, 2024 15:21 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californie, 17 avr. 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq : CLPT) (la « Société »), une société mondiale spécialisée dans les dispositifs, de thérapie cellulaire et...
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
April 16, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
March 19, 2024 08:07 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
March 12, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro reports 32% growth in fourth quarter as compared to fourth quarter of 2022. Biologics revenue increased 49% YOY.
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
March 11, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces peer-reviewed publication showing correlation of software lesion size to histopathology, only FDA-cleared laser with correlation
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
March 01, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...